News

In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening

This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States. “The

CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing

The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from

The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small

In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH).

Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This

Under the binding agreement, the companies will work together to provide solutions for coronaviruses, including SARS-CoV-2, the novel coronavirus responsible for COVID-19. GSK will make an equity investment

The late-stage trial met both the co-primary endpoints, with Nucala added to standard of care delivering statistically significant improvements in the size of nasal polyps at week 52